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Targeting brain tumor cAMP: the
case for sex-specific therapeutics
Nicole M. Warrington 1, Tao Sun 1 and Joshua B. Rubin 1, 2*
1Department of Pediatrics, Washington University School of Medicine, St Louis, MO, USA, 2Department of Anatomy and
Neurobiology, Washington University School of Medicine, St Louis, MO, USA
A relationship between cyclic adenosine 3′, 5′-monophosphate (cAMP) levels and brain
tumor biology has been evident for nearly as long as cAMP and its synthetase, adenylate
cyclase (ADCY) have been known. The importance of the pathway in brain tumorigenesis
has been demonstrated in vitro and in multiple animal models. Recently, we provided
human validation for a cooperating oncogenic role for cAMP in brain tumorigenesis when
we found that SNPs in ADCY8were correlated with glioma (brain tumor) risk in individuals
with Neurofibromatosis type 1 (NF1). Together, these studies provide a strong rationale
for targeting cAMP in brain tumor therapy. However, the cAMP pathway is well-known to
be sexually dimorphic, and SNPs in ADCY8 affected glioma risk in a sex-specific fashion,
elevating the risk for females while protecting males. The cAMP pathway can be targeted
at multiple levels in the regulation of its synthesis and degradation. Sex differences in
response to drugs that target cAMP regulators indicate that successful targeting of the
cAMP pathway for brain tumor patients is likely to require matching specific mechanisms
of drug action with patient sex.
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Brain Tumors and Camp: Some Basics
Soon after its discovery, it became clear that cAMP was a ubiquitous second messenger and that
normal physiology was dependent upon precise regulation of its synthesis and degradation. As
a corollary, investigations rapidly ensued to determine whether pathology was associated with
dysregulation of cAMP levels. In 1971,multiple studies were published that associated differences in
cAMP levels with differences between normal and cancer cells (Heidrick and Ryan, 1971; Johnson
et al., 1971; Otten et al., 1971). Elevated levels of adenylate cyclase (ADCY) activity and cAMP
levels were associated with normalization of cell morphology, restoration of contact inhibition and
reduced growth rates in neoplastic cells. Subsequently, an inverse relationship between cAMP levels
and tumor grade was established for several types of brain tumors (Furman and Shulman, 1977).
High ADCY activity and cAMP levels were found in benign brain tumors, while lower ADCY
activity and cAMP levels were correlated with greater degrees of malignancy.
Today, there is good reason to think that elevating cAMP will be an important therapeutic for
brain tumors, and here, we will review key data validating cAMP as a target in the treatment of
brain tumors. We will also discuss the significant sexual dimorphism in this pathway. Evidence for
sex-specific responses to drugs that target cAMP indicate that knowledge of sex differences must
be incorporated into preclinical and clinical investigations if cAMP is to be successfully targeted
in the treatment of brain tumors. It is our perspective that targeting cAMP in the treatment of
brain tumors will be a critical test case for the importance of sex-specific treatment of cancer.
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Adenylate Cyclase and Tumorigenic
Mechanisms
Differences in cAMP synthesis arise through differences in
expression, subcellular localization and activation of nine
different membrane bound ADCYs and one soluble ADCY
(Cooper and Tabbasum, 2014). Variation in stimulation and
inhibition by heterotrimeric G protein subunits, calcium,
multiple protein kinase C isoforms and calcium/calmodulin-
dependent protein kinase results in unique regulatory “codes” for
activation of different ADCY isoforms (Sunahara and Taussig,
2002; Cooper and Tabbasum, 2014). These non-overlapping
mechanisms of regulation potentially create alternate landscapes
for the interaction between primary oncogenic events in brain
tumorigenesis and total ADCY activity. Medulloblastoma and
the localization of ADCY3 to the base of the primary cilia
(Figure 1A), provides a compelling illustration (McIntyre et al.,
2015).
Medulloblastoma is the most commonmalignant brain tumor
of childhood. There are currently four recognized subtypes
of medulloblastoma, and one involves mutational activation
of the sonic hedgehog (SHH) pathway (Gibson et al., 2010;
Northcott et al., 2010; Cho et al., 2011; Kool et al., 2012).
Sonic hedgehog signaling involves the activation of a receptor
and signaling complex within the primary cilium (Figure 1B).
Activation of the pathway results in translocation of the
transcription factor Gli2 to the nucleus (Ruat et al., 2012).
This key event is blocked by cAMP and protein kinase A
(PKA), possibly through stabilization of the complex between
Gli2 and Suppressor of Fused (Sufu) (Tuson et al., 2011;
Mukhopadhyay et al., 2013). The localization of ADCY3 and
cAMP generation to the base of the primary cilium provides a
potent and localized mechanism for inhibition of sonic-induced
transcription.
A number of experimental findings suggest that the
positioning of ADCY3 in primary cilia anatomy may support
a cooperative role for cAMP regulation in SHH pathway
dependent medulloblastoma-genesis. Sonic hedgehog driven
medulloblastoma arises from the cerebellar granule neuron
lineage (Oliver et al., 2005). Two key G protein-coupled
receptors, PAC1 and CXCR4, are expressed in normal and
neoplastic derivatives of this lineage, and function to elevate
and suppress cAMP levels, respectively (Klein et al., 2001;
Nicot et al., 2002; Rubin et al., 2003). Each pathway is known
to powerfully regulate SHH signaling in a cAMP dependent
fashion. Mice with combined deficiency of the genes for the SHH
receptor, Patched (Ptc), and the PAC1 ligand, Pituitary Adenylate
Cyclase Activating Peptide (PACAP), have increased incidence of
medulloblastoma compared to mice with Ptc deficiency alone
(Lelievre et al., 2008). The effect of PAC1 activation was recently
demonstrated to involve inhibition of ciliary translocation
of Gli2 in a PKA-dependent manner (Niewiadomski et al.,
2013). In related studies, deletion of the alpha subunit of
the stimulatory heterotrimeric G protein Gs also resulted in
SHH-driven medulloblastoma (He et al., 2014). Together these
genetically engineered mouse models indicate that diminution
in the ability to elevate cAMP levels within the granule neuron
FIGURE 1 | Cyclic AMP signaling at the primary cilium regulates sonic
hedgehog signaling. (A) The primary cilium (asterisk, green) in a
medulloblastoma cell is clearly visible under direct immunofluorescence using
an antibody directed against acetylated tubulin (Sigma). An antibody directed
against ADCY3 (red, Santa Cruz) reveals its localization at the base of the
primary cilium. The nucleus is counterstained blue with DAPI. Scale bar equals
10 microns. (B) Schematic of the primary cilium indicating the potential
interactions between the sonic hedgehog and the CXCR4 pathways. The inset
is the cilium from (A). In the schematic are shown the plasma membrane (pale
blue) with surface localized CXCR4, acetylated tubulin within the cilium (green),
ADCY 3 at the base of the cilium (red), sonic hedgehog signaling components
(white), CXCR4 (multi-colored), and the nucleus (dark blue). Activation of
CXCR4 results in inhibition of ADCY3, local decreases in cAMP levels,
decreased PKA activation and enhanced GLI localization to the nucleus.
Increased sonic hedgehog signaling results in increased surface localization of
CXCR4.
lineage is permissive for tumorigenesis in a SHH-dependent
fashion.
Consistent with these findings are studies exploring the
relationship between the SHH pathway and the Gαi-coupled
receptor, CXCR4. Levels of CXCR4 expression identify two
subgroups within the SHH subtype of medulloblastoma
(Sengupta et al., 2012). Maximal tumor growth in murine
and human models of SHH subtype medulloblastoma is
dependent upon co-activation of SHH and the CXCR4
pathway. Surface localization of CXCR4 and consequently,
CXCR4-mediated Gαi activation and cAMP suppression, is
stimulated by the SHH pathway, creating a positive feedforward
loop for suppression of cAMP levels and activation of Gli-
mediated transcription (Sengupta et al., 2012). Blockade of
CXCR4 signaling, and elevation of cAMP levels, with specific
small molecule antagonists has potent anti-tumor effects in
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intracranial xenograft models of SHH driven medulloblastoma
(Rubin et al., 2003; Yang et al., 2007; Barone et al., 2014).
Phosphodiesterases and Brain Tumors
While modulation of ADCY activity coordinates cAMP
production with activity in other signaling pathways and
provides some spatial localization for cAMP production,
finer aspects of the compartmentalization of cAMP signaling
occur through subcellular localization and regulated activity
of phosphodieseterases (PDE) (Bender and Beavo, 2006).
Overexpression of the cAMP specific PDEs (PDE4, 7, and 8) is a
frequent event in cancer, including brain tumors (Goldhoff et al.,
2008; Brooks et al., 2014; Dong et al., 2015). An examination
of 37 human pediatric and adult brain tumor specimens
including astrocytomas, medulloblastomas, oligodendrogliomas,
ependymomas, and meningiomas all exhibited high levels of
PDE4A expression, primarily in tumor cells (Goldhoff et al.,
2008). Furthermore, overexpression of a super-short, brain
specific isoform of PDE4A, PDE4A1, accelerated brain tumor
growth in mice bearing intracranial xenografts of human
glioma cells (Goldhoff et al., 2008). Inhibition of PDE4 activity
with the drug Rolipram inhibited growth in those tumors and
in mouse xenografts of human medulloblastoma cells (Yang
et al., 2007; Goldhoff et al., 2008). Gene expression profiling
of medulloblastoma indicates that cAMP signaling and altered
expression of PDE1C and PDE4B is a characteristic feature of
Group D tumors (Northcott et al., 2010).
PDE7B is another cAMP specific phosphodiesterase that is
frequently upregulated in glioblastoma (GBM) and is negatively
correlated with survival (Brooks et al., 2014). Among the
four molecular subtypes of GBM, PDE7B is expressed at the
highest levels in Classical, followed by Neural, Mesenchymal, and
Proneural subtypes (Brooks et al., 2014). Increased expression of
PDE7B was observed in a subset of tumor cells with enhanced
tumor initiating capacity, and overexpression of PDE7B in a
U87 intracranial xenograft model of GBM transformed the
typical circumscribed pattern of intracranial U87 growth into
a highly invasive one. These observations suggest that similar
to the case of PDE4A1, PDE7B, and cAMP suppression may
be critical mediators of tumorigenic mechanisms in GBM,
particularly in the Classical and Neural subtypes (Brooks et al.,
2014).
Phosphodiesterase expression can be regulated by microRNAs
(mirs) and this mechanism has been correlated with tumor
biology and therapeutic responses. In diffuse large B cell
lymphoma, decreased mir-124 expression led to increased
PDE4B expression and subsequent insensitivity to glucocorticoid
treatment (Kim et al., 2015). In GBM, mir-33a expression has a
negative prognostic effect and is necessary for maintenance and
self-renewal of the tumor-initiating cell population. This critical
function of mir-33a was dependent upon its direct regulation of
PDE8A andUVRadiation Resistance AssociatedGene (UVRAG)
and their downstream mediators, PKE, and Notch, respectively
(Wang et al., 2014). Together with data regarding PDE7B
functions inGBM, these findings indicate that the cAMPpathway
is essential for tumor initiating cell function. This is a key
consideration for promoting cAMP elevating approaches for
brain tumor treatment.
The large number of PDE isoforms that are generated
from 21 different genes in 11 different families provides
for exquisite specialization in cAMP signaling through the
formation of diverse PDE signalosome complexes (Azevedo
et al., 2014). Phosphodiesterase signalosome complexes are
comprised of PDEs in association with scaffolding proteins such
as AKAPs, and regulators of cAMP signaling like EPACs at
specific subcellular sites that allow for the precise localization of
cAMP gradients and subcellular compartmentalization of cAMP
signaling. For example, PDE8A complexes with AKAP and Raf-
1, a potent activator of MAPK signaling to inhibit PKA mediated
inactivation of Raf-1 and MAPK signaling (Brown et al., 2013).
PDE4 isoforms are targeted to specific subcellular compartments
by unique amino termini. For example, PDE4A1 contains an
amino terminal TAPAS-1 domain that localizes it to the trans
Golgi complex (Baillie et al., 2002), suggesting that modulation
of cAMP levels and its downstream effectors in this domain are
critical for PDE4A1’s role in brain tumor growth. The peri-Golgi
domain is in close proximity to the centrosome and these regions
are thought to share a cAMP pool (Verde et al., 2001; Terrin
et al., 2012). Modulation of this pool by displacement of localized
PDE4D3 has been shown to directly induce cell-cycle arrest
(Terrin et al., 2012). Interestingly, protein kinase A is localized to
this PDE4D3 signalosome by interacting with AKAP9, which is
altered in expression in medulloblastoma (Northcott et al., 2010).
Cyclic AMP Plays a Cooperating Role in
Brain Tumorigenesis
Thework of He et al. (2014) and Lelievre et al. (2008) indicate that
AC-mediated cAMP regulation plays an important cooperating
role in the genesis of medulloblastoma. The use of genetically
engineered mouse models (GEMM) of other brain tumors
has also confirmed the importance of PDE activity to brain
tumorigenesis. In a GEMM of Neurofibromatosis type 1 (NF1),
we found that gliomas could be induced by creating foci of PDE-
driven reductions in levels of cAMP (Warrington et al., 2010).
NF1 predisposes affected individuals to a number of neoplasms
in the central and peripheral nervous systems and other tissues.
The most common central nervous system tumor is a low-grade
astrocytoma of the optic pathway that most commonly affects
children less than 10 years of age (Rubin and Gutmann, 2005).
The factors that dictate the temporal and spatial distribution of
these tumors are not completely understood. However, there is a
clear requirement for the combined effects of: (1) homozygous
loss of neurofibromin function in tumor progenitors, (2)
heterozygous loss of neurofibromin function in stromal cells of
the microenvironment, and (3) other factors specific to the most
commonly affected brain regions, such as differences in stem
cell populations or growth regulatory/differentiation pathways.
Neurofibromin functions as a negative regulator of RAS, and
increased RAS activity is accepted as the primary driver of low-
grade gliomagenesis through its activation of ERK and AKT
pathways (Ratner and Miller, 2015). However, the additional
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requirements for tumorigenesis indicate that complete loss of
NF1 and hyperactivation of RAS in tumor progenitors is not
sufficient for gliomagenesis and that cooperating molecular
events must be at play. We described an “oncogenic” mode of
CXCR4 signaling that we hypothesized would be a cooperating
event in NF1-associated gliomagenesis (Rubin, 2009). We
defined this mode of CXCR4 signaling as a loss of receptor
desensitization and capacity for sustained suppression of cAMP
levels (Warrington et al., 2007; Sengupta et al., 2012; Woerner
et al., 2012). The loss of desensitization was the result of ERK
dependent phosphorylation and inhibition of GRK2, which
we showed resulted in decreased CXCR4 phosphorylation and
sustained suppression of cAMP in response to receptor ligation
with CXCL12 (Warrington et al., 2007). As we had also shown
that CXCL12 was abundant in low-grade gliomas in tumor-
associated endothelial cells, microglia, and entrapped neurons,
we hypothesized that low levels of cAMP would promote tumor
formation. We tested this hypothesis by forcing expression of
PDE4A1 in the brains of NF1 GEMM. This model has a highly
stereotypical pattern of tumor formation involving the optic
pathway alone, and we postulated that if cAMP suppression
was a key cooperating event, then expression of PDE4A1 in
the cortex would result in the formation of “ectopic” cortical
tumors. We chose PDE4A1 for these experiments because the
PDE4 family has been shown to be responsible for of the
bulk of the cAMP hydrolyzing activity in cells (Conti et al.,
2003), and PDE4A1 is a brain specific, super short isoform of
PDE4A (Huston et al., 2006). This super short form lacks the
regulatory and protein-complexing domains present in longer
PDE4 isoforms. Therefore, the effects of PDE4A1 overexpression
can be directly attributed to increased cAMP hydrolysis. We
found that PDE4A1 expression resulted in foci of decreased
cAMP levels that were significantly correlated with the genesis of
cortical “ectopic” tumors (Warrington et al., 2010). Furthermore,
inhibition of PDE4 with Rolipram blocked the growth of
spontaneous tumors in this GEMM (Warrington et al., 2010).
Thus, in both medulloblastoma and NF1-associated glioma,
primary oncogenic events are mechanistically complemented by
decreased levels of cAMP.
Abnormal PDE expression and activity has also been
implicated in chronic lymphocytic leukemia (Zhang et al., 2008),
lung cancer (Pullamsetti et al., 2013) and colon cancer (McEwan
et al., 2007). Similar to the case for polymorphisms in ADCY and
cancer risk, single nucleotide variations in PDE8A and PDE11A
have been associated with adrenocortical carcinoma (Oliver et al.,
2005) as well as cancer of the testes (Klein et al., 2001) and
prostate (Nicot et al., 2002).
Cyclic AMP as a Target for Brain Tumor
Therapy
The clear correlation between low levels of cAMP and enhanced
brain tumorigenesis, brain tumor grade and brain tumor
growth, has naturally prompted efforts to develop cAMP
elevating approaches to brain tumor treatment. Early efforts
utilizing cAMP analogs like 8-chloro-cAMP were associated
with dose-limiting toxicities (Propper et al., 1999). Subsequent
clinical trials of targeted agents with potential to modulate cAMP
levels include G protein coupled receptor (GPCR) agonists and
antagonists, as well as stimulators and inhibitors of ACs and
PDEs. Notable among the potential clinically available GPCR
antagonists that can elevate cAMP are the CXCR4 antagonists
AMD3100 (Plerixafor, Genzyme) and POL6326 (Polyphor).
AMD3100, AMD3465, and POL5551, also CXCR4 antagonists,
have all been shown to block intracranial brain tumor growth
in several experimental models, and this activity was correlated
with the elevation of cAMP levels in models of GBM and
medulloblastoma (Rubin et al., 2003; Yang et al., 2007; Barone
et al., 2014). Key to CXCR4 antagonism is the blockade of critical
tumor-stromal interactions that occur within the specialized
perivascular stem cell niche (PVN) (Rao et al., 2012). In
combination with Avastin, POL5551 was shown to block both
the formation of new PVN and the function of existing PVN to
maintain brain tumor stem cells (Barone et al., 2014).
More specific manipulation of cAMP levels is possible
through the use of agents and strategies to increase cAMP
synthesis or decrease its degradation. Fundamental principles of
pharmacology indicate that inhibition of degradation can have
more potent and stable effects on cAMP levels than stimulation
of its synthesis (Bender and Beavo, 2006). Consequently,
PDE inhibition as a strategy for the therapeutic elevation of
cAMP has a long history (Sengupta et al., 2011). Early efforts
involved general PDE inhibitors like pentoxyphylline or caffeine,
which have both pan-PDE inhibitory and adenosine agonist
activities. Non-specific PDE inhibition for cancer applications
was complicated by excessive toxicity. As the full breadth of PDE
genetics, biochemistry and cell biology became apparent, non-
specific approaches gave way to targeted inhibition of specific
PDE families. Among the most productive efforts has been
the development of a repertoire of PDE4 antagonists. In fact
effective PDE4 antagonists for brain tumor therapy may already
be clinically available for other applications such as COPD
(Sengupta et al., 2011).
Sex Differences in the cAMP Pathway
Demand a Sex-specific Approach to Its
Targeting
Drug selection for cAMP elevation should proceed carefully and
patient selection should be precise. In this regard it will be
critically important to recognize the growing body of evidence
for significant sex differences in the pathophysiology of human
disease and how these might translate into sex differences in
therapeutic responses to targeted agents. Sexual dimorphism in
the cAMP pathway, and in PDE activity specifically, is likely to
impact on the efficacy and appropriateness of specific inhibitors
for individual patients.
There is ample evidence that sex differences exist in cAMP
levels. In multiple experimental systems, sex differences have
been measured in the expression and activity of cAMP regulators
and resultant cAMP levels. For example, neurons in the pontine
nucleus of the rat exhibit sexually dimorphic response to
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FIGURE 2 | Sex differences in the cAMP pathway. (A) Activation of Gαi
was measured by Western blot for the GTP loaded and total Gαi forms using
a kit from Neweast Biosciences as described (Sengupta et al., 2012). Male
and female Nf1−/− astrocytes prepared as described (Warrington et al.,
2015), serum starved for 48 h, and treated with vehicle (PBS) or CXCL12
(0.1 ug/ml, 5min). Shown is a representative Western blot and a plot of the
fold differences relative to the basal male condition, in the mean and SEM of
the fraction of GTP loaded (active) to total Gαi. N = 4. *p < 0.05, **p < 0.005
as determined by two-tailed t-test. Accompanying Western blots of CXCR4
with actin loading control indicate that differences in Gαi activation are not
the result of differences in CXCR4 expression. (B) Cyclic AMP levels were
measured by ELISA as previously described (Warrington et al., 2015) in male
and female Nf1−/− astrocytes treated with Rolipram (20 uM). N = 3. P-value
was determined by Two-Way ANOVA.
corticotropin-releasing factor (CRF). When treated with CRF,
female neurons exhibit both greater cAMP elevation and greater
PKA activation compared to male neurons. This has been
proposed to be the consequence of greater coupling between Gαs
and the CRF receptor in female neurons (Valentino et al., 2013).
We have made similar observations about the coupling between
CXCR4 and Gαi in murine astrocytes. Male and female Nf1−/−
astrocytes treated for 5min with CXCL12 (0.1µg/ml) exhibit
significantly different levels of GTP loading of Gαi despite equal
expression of CXCR4 (Figure 2A).
In rat myocytes, greater PDE4B expression leads to lower
baseline cAMP levels in female cells. This results in decreased
activation of PKA, smaller calcium transients and less forceful
contractions than in their male counterparts (Parks et al., 2014).
Additionally, PDE3B expression is higher in female endothelial
cells rendering them more responsive to treatment with a PDE3
inhibitor than male endothelial cells (Wang et al., 2010).
Sex differences in expression and function of cAMP
regulators have also been demonstrated in glioma precursor
cells derived from a mouse model of NF1. In this model,
astrocytes with targeted deletion of neurofibromin Nf1−/− are
poised to be tumorigenic in the appropriate setting, which
includes requirements for heterozygous loss of neurofibromin
in tumor stromal elements and other, as yet to be fully
defined factors, that stereotypically promote tumorigenesis in
the optic nerves and optic chiasm. Male Nf1−/− astrocytes
expressed more Gnai3 and less Gnas transcript than female
cells (Warrington et al., 2015). Female Nf1−/− astrocytes
expressed significantly lower levels of Adcy3 and more Adcy5
levels, and higher Pde4a1 levels than male astrocytes. In
response to treatment with forskolin, a pan activator of AC,
in the presence of IBMX, a pan PDE inhibitor, female cells
exhibited greater cAMP synthetic capacity, while in cells
treated with forskolin alone, males showed greater capacity to
activate phosphodiesterases and block forskolin-induced cAMP
elevation. These data indicate that sex differences in expression
of cAMP regulators render male and female cells differentially
sensitive to the effects of drugs that target the activity of cAMP
regulators.
Evidence for sexual dimorphism in the cAMP pathway is also
evident in human data. A single nucleotide polymorphism (SNP)
array analysis of polymorphisms in the cAMP pathway with
DNA from individuals with NF1 with and without optic pathway
gliomas revealed that polymorphisms in ADCY8 (AC8) increase
glioma risk in female patients with NF1, but are protective against
glioma in male patients (Warrington et al., 2015). Reports of
sex specific effects of SNPs in ADCY7 (rs2302717) in alcohol
dependence (Desrivieres et al., 2011) and SNPs in PDE4B in
schizophrenia (Pickard et al., 2007) suggest there is a broader
importance to sex differences in cAMP regulation to human
disease.
We would propose that therapeutic cAMP elevation is an ideal
setting to test the hypothesis that sexual dimorphism in the cAMP
pathway will render males and females differentially sensitive to
specific cAMP modulating agents. We previously reported that
PDE4 inhibition with Rolipram had significant anti-brain tumor
effect in multiple brain tumor models (Yang et al., 2007; Goldhoff
et al., 2008;Warrington et al., 2010).We performed a preliminary
determination of whether the reported sex differences in PDE4
isoform expression in Nf1−/− astrocytes would render male and
female Nf1−/− astrocytes differentially sensitive to Rolipram.
Male Nf1−/− astrocytes exhibit lower basal levels of cAMP and
are insensitive to Rolipram (Figure 2B). In contrast, female
Nf1−/− astrocytes exhibit higher baseline levels of cAMP and
these levels further increase with Rolipram treatment. Thus,
female brain tumor patients may be more responsive to Rolipram
treatment than male brain tumor patients.
The multiplicity of agents that can target different levels of the
cAMP regulatory pathways from GPCR through AC and PDE
should allow for exhaustive determination of how significant the
effects of sex are on cAMP regulation and therapeutic responses
to cAMP modulation. Only with this kind of knowledge can we
hope to harness the full power of cAMP elevating agents to treat
cancer.
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